ViroMed earns USFDA approval for phase 2 clinical trials of ALS treatment
Oct 4, 2016
[THE INVESTOR] Viromed announced on Oct. 4 that it has obtained approval from the US Food and Drug Administration to enter phase 2 clinical trials of VM202, its amyotrophic lateral sclerosis treatment. The gene therapy developed by the South Korean pharmaceutical company has been classified as an orphan drug by the USFDA during phase 1 clinical trials due to the effectiveness it displayed with ALS patients. The phase 2 trial is expected to last 9 months with 84 patients participating in the proc